胶质母细胞瘤中PD-L1肿瘤表达与不良预后及全身免疫抑制相关
研究对352例胶质母细胞瘤标本(313例初治切除,39例配对复发)行免疫组化检测PD-L1表达,并分析其与肿瘤浸润淋巴细胞、绝对淋巴细胞计数及中性粒细胞-淋巴细胞比值的关联。初治肿瘤中31%(98/313)存在膜性PD-L1表达,配对复发肿瘤中为46%(18/39)。PD-L1表达与肉瘤样分化区域更常见、较低淋巴细胞计数及较高NLR相关,且为独立的不良预后标志。
要点
- 初治胶质母细胞瘤中31%(98/313)存在膜性PD-L1表达,配对复发肿瘤中为46%(18/39)。
- PD-L1表达与肿瘤浸润淋巴细胞密度及位置显著相关(p < 0.001)。
- PD-L1表达肿瘤更常伴肉瘤样分化区域(p < 0.001),并与诊断时较低淋巴细胞计数(p = 0.018)及较高NLR(p = 0.004)相关。
核心结论
- PD-L1表达在胶质母细胞瘤生物学中可能起作用,与患者较差总生存、全身炎症状态及免疫抑制相关。
研究设计与样本
- 收集352例胶质母细胞瘤标本(313例初治切除,39例配对复发),详细刻画肿瘤浸润淋巴细胞的存在、密度和位置,采用绝对淋巴细胞计数和中性粒细胞-淋巴细胞比值(NLR)分析全身炎症与免疫抑制,并行免疫组化评估PD-L1表达。
主要发现
- 膜性PD-L1表达见于31%(98/313)初治肿瘤和46%(18/39)配对复发肿瘤。
- 肿瘤浸润淋巴细胞见于26%(82/313)原发肿瘤,其密度和位置与PD-L1表达显著相关(p < 0.001)。
- PD-L1表达肿瘤更常出现肉瘤样分化区域(p < 0.001),诊断时淋巴细胞计数较低(p = 0.018),NLR较高(p = 0.004)。
- PD-L1表达为独立的不良预后标志。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma is the most common primary malignant brain tumor in the adult, whose grim prognosis largely relates to the absence of effective treatment targets. Given its success in other cancers, immunotherapy has been trialed in glioblastoma and failed to demonstrate the expected benefit. Importantly, these disappointing results highlight the importance of understanding the unique and transforming biology of glioblastoma and its microenvironment. Our goal was to evaluate and characterize the expression of PD-L1 through immunohistochemistry in a large glioblastoma cohort. We further studied PD-L1 expression-associated prognosis and its correlation to systemic and neuropathological parameters. METHODS: A series of 352 glioblastoma specimens (313 initial resection, 39 matched recurrences) was collected, with a detailed characterization of tumor neuropathological characteristics, including the presence, density and location of tumor infiltrating lymphocytes (TIL). Two hematological markers, absolute lymphocyte count and neutrophil-lymphocyte ratio (NLR), were used to analyze and correlate with systemic inflammation and immunosuppression. Immunohistochemistry was performed to evaluate PD-L1 expression. RESULTS: Membranous PD-L1 expression was identified in 31% (98/313) of newly diagnosed and 46% (18/39) of matched recurrent tumors. TIL were found in 26% (82/313) of primary tumors and both density and location were found to be significantly associated with PD-L1 expression (p < 0.001). Interestingly, PD-L1 expressing tumors had more frequently areas with sarcomatous differentiation (p < 0.001) and were significantly associated with lower lymphocyte count (p = 0.018) and higher NLR ratio (p = 0.004) upon diagnosis. Importantly, PD-L1 expression was an independent poor prognostic marker in our cohort. CONCLUSION: Taken together, our data points to a putative role for PD-L1 expression in glioblastoma biology, which correlates to poor patient overall survival, as well as with a general systemic inflammatory status and immunosuppression.
引用
- Noronha C, Ribeiro AS, Taipa R, et al. PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma. J Neurooncol. 2022. PMID: 35066764. doi:10.1007/s11060-021-03907-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。